FDA Approves Drug to Combat Infections
From Associated Press
WASHINGTON — The Food and Drug Administration said Tuesday that it had approved a new genetically engineered drug to boost the infection-fighting ability of cancer patients who get transplants of their own bone marrow.
The drug promotes the growth of infection-fighting white blood cells which are formed in the bone marrow. It will be sold by Immunex Corp. of Seattle, the developer, under the name Leukine and by Hoechst-Roussel Pharmaceuticals Inc. under the name Prokine.
Experts have said the drug could eventually be used in fighting AIDS.
